SCHEMBL3578041

SCHEMBL3578041

CC(=O)NCC1(N2CCC(F)CC2)COC(=O)N1c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 3/20 0.32
OPRL1 P41146 3/20 0.32
OGA O60502 2/20 0.32
ALKBH5 Q6P6C2 1/20 0.32
FTO Q9C0B1 1/20 0.32
HTR2A P28223 2/20 0.32
HTR2C P28335 2/20 0.32
HTR2B P41595 2/20 0.32
MTNR1A P48039 2/20 0.32
MTNR1B P49286 1/20 0.32
MYC P01106 2/20 0.32
WDR5 P61964 2/20 0.32
DRD3 P35462 2/20 0.32
METAP2 P50579 2/20 0.31
DRD2 P14416 1/20 0.31
LMNA P02545 1/20 0.31
MAOA P21397 1/20 0.31
PTGS1 P23219 1/20 0.31
MAOB P27338 1/20 0.31
CALML3 P27482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3570224 0.77 ALDH1A1 (0.33) LMNA
SCHEMBL3578040 0.67 IDH1 (0.33) OPRM1OPRL1
SCHEMBL3576644 0.66 HSD11B1 (0.37)
SCHEMBL3572023 0.65 MAOA (0.35) DRD3DRD2MAOA
Acetamide SCHEMBL3579500 0.62 ALDH1A1 (0.35) LMNA
SCHEMBL3578038 0.62 MTNR1A (0.36) MTNR1AMTNR1BLMNAMAOAPTGS1
SCHEMBL5418053 0.62 IDH1 (0.38)
SCHEMBL7812799 0.61 ALDH1A1 (0.35) METAP2
SCHEMBL3570167 0.60 IDH1 (0.38) OPRM1
SCHEMBL2732938 0.59 HSD11B1 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8729269-B2 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy WOCKHARDT LIMITED (IN) 2014-05-20 US disclosed
US-20100144735-A1 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY WOCKHARDT LIMITED 2010-06-10 US disclosed
US-7687627-B2 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy WOCKHARDT LIMITED (IN) 2010-03-30 US disclosed
EP-1664038-A2 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED I IN VIVO /I EFFICACY Wockhardt Limited (IN) 2006-06-07 EP disclosed
US-20050143421-A1 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy WOCKHARDT LIMITED 2005-06-30 US disclosed
WO-2005054234-A2 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY WOCKHARDT LIMITED (IN) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144735-A1 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY GMPS, MPO, ARG1 OPRM1 3474/4885OPRL1 3920/4885OGA 972/4885
US-20050143421-A1 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy GMPS, MPO, ARG1 OPRM1 3474/4885OPRL1 3920/4885OGA 972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.